Demencia

Beta-sitosterol is a plant-derived phytosterol with established clinical evidence for improving urinary symptoms and flow in men with BPH. A Cochrane review of four randomized, double-blind, placebo-controlled trials (519 men) found beta-sitosterol treatments significantly improved urinary symptom scores and urinary flow measures compared to placebo.

Campesterol has demonstrated uroprotective potential in a preclinical study of interstitial cystitis and is a component of phytosterol blends evaluated for BPH-related urinary symptoms. Its inhibition of 5α-reductase type 2 mechanistically supports a role in androgenic regulation of urinary flow. Clinical evidence is mixture-based rather than campesterol-specific.

A double-blind, placebo-controlled, dose-ranging clinical trial (Cochrane Central registered) found a Ganoderma-containing extract significantly reduced prostate volume in BPH patients. G. lucidum's 5α-reductase inhibitory activity provides a mechanistic basis for improving urinary symptoms.

Lycopene, a carotenoid concentrated in tomatoes, has been studied for BPH and prostate cancer prevention. While a systematic review found no statistically significant reduction in BPH incidence as monotherapy, lycopene inhibits prostate cell growth in vitro, shows anti-inflammatory effects, and performs better in combination with other prostate-active ingredients such as tamsulosin in clinical trials.

Stinging nettle root (Urtica dioica) is used in European phytotherapy for BPH-related urinary symptoms and has been approved by the German Commission E for this indication. A systematic review and meta-analysis of five RCTs (1,128 patients) found significant improvements in IPSS, peak urinary flow rate, and prostate volume compared to placebo.

Beta-sitosterol supplementation has been shown in multiple RCTs to significantly improve peak urinary flow rate (Qmax) and reduce post-void residual urine volume in men with BPH. The Lancet trial showed peak flow rising from 9.9 to 15.2 mL/s with active treatment vs. placebo.

Multiple RCTs and a Cochrane review confirm that standardized Prunus africana bark extract increases peak urine flow and reduces urinary retention in men with BPH. The Cochrane review (18 trials, n=1,562) quantified a 23% increase in peak urine flow versus placebo. This is one of the most robustly documented urinary-flow benefits of any herbal supplement.

Pumpkin seed and pumpkin seed oil (Cucurbita pepo) have clinical evidence supporting their use for BPH-related urinary symptoms in men. A randomized clinical trial comparing pumpkin seed oil to tamsulosin found meaningful symptom relief, and a 24-month noninterventional study confirmed improvements in IPSS and quality of life without negative sexual effects. A meta-analysis reported a mean IPSS reduction of 5.72 points and improved peak urinary flow rate by 3.15 mL/sec.

Pygeum (Prunus africana / Pygeum africanum) bark extract has been used in European medicine since the 1960s for BPH-related urinary symptoms. A Cochrane systematic review and quantitative meta-analysis of 18 RCTs (1,562 men) found men using Pygeum were more than twice as likely to report improvement in overall symptoms versus placebo, with a 23% increase in peak urine flow and 24% reduction in post-void residual volume.

A double-blind, placebo-controlled RCT (Noguchi et al., 2008) in 88 men with LUTS found 6 mg/day reishi extract for 12 weeks significantly improved International Prostate Symptom Score. Reishi shows the strongest 5-alpha reductase inhibitory activity among 19 tested mushrooms. However, effects on objective urine flow rate are less consistent; symptom scores (urgency, frequency) improve more reliably than measured peak flow.

Saw palmetto (Serenoa repens) liposterolic extract at 320 mg/day is among the most studied phytotherapies for BPH-related urinary symptoms in men. Multiple RCTs and earlier meta-analyses reported mild-to-moderate improvements in urinary flow, nocturia, and symptom scores. More recent Cochrane reviews and high-dose RCTs show inconsistent results versus placebo, making overall evidence mixed but substantial.

Zinc is accumulated in uniquely high concentrations in healthy prostate tissue and is depleted in BPH and prostate cancer. Epidemiological and laboratory studies associate lower zinc status with BPH progression, and supplemental zinc has been found in clinical practice to improve urine flow and reduce residual volume in men with BPH, though large rigorous placebo-controlled trials on zinc supplementation alone for urinary flow are limited.

Buchu (Agathosma betulina and related species) is a traditional South African medicinal plant used historically for urinary tract conditions, including urinary difficulty and frequency in men. It has been included in official pharmacopoeias and used as a urinary antiseptic and diuretic in folk and herbal medicine, though clinical trial data specific to male urinary flow are limited.

Corn silk (Zea mays stigma) has a long history of traditional use in North American and European folk medicine as a urinary demulcent and diuretic, used to ease urinary flow and reduce symptoms of urinary difficulty in men. It contains flavonoids, saponins, tannins, and polysaccharides that may support urinary tract function, though robust clinical trials in men specifically for BPH or urinary flow are lacking.

Dwarf nettle (Urtica urens) has been used traditionally alongside stinging nettle in European folk medicine for urinary complaints in men, particularly urinary frequency and incomplete bladder emptying associated with enlarged prostate. Its traditional use for men's urinary health parallels that of stinging nettle root, though clinical evidence specific to Urtica urens for BPH/LUTS is far more limited than for Urtica dioica root.

Horsetail (Equisetum arvense) has been used in European and Asian traditional medicine as a diuretic and urinary tonic for men's urinary complaints, including weak stream and frequency. The German Commission E has approved horsetail as a diuretic for irrigation therapy in urinary tract conditions. Clinical evidence specifically for BPH or urinary flow improvement in men is limited, with most support coming from traditional use and diuretic pharmacology.